Cadrenal Therapeutics, Inc. Common Stock
CVKDNASDAQHealthcare● Active
$4.27
+$0.06(+1.31%)
Market Cap$12233073
P/E Ratio—
52W High$15.99
52W Low$4.145
Cadrenal Therapeutics, Inc. Common Stock (CVKD) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CVKD · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$1.04
Est. -$1.51 · +31.1%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
CVKD reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 10, 2026 | -$1.55 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$1.51 | -$1.04 | +31.1% | — | — | — |
| ▼ Q1 FY2026 | Mar 31, 2026 | -$1.17 | -$1.41 | -20.5% | — | — | — |
| ▲ Q4 FY2025 | Nov 10, 2025 | -$1.55 | -$1.31 | +15.5% | — | — | — |
| ▼ Q3 FY2025 | Aug 11, 2025 | -$1.60 | -$1.87 | -16.9% | — | — | — |
| ▼ Q2 FY2025 | May 8, 2025 | -$1.64 | -$2.09 | -27.4% | — | — | — |
| ▼ Q1 FY2025 | Mar 13, 2025 | -$1.71 | -$2.74 | -60.2% | $0.00B | — | — |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$1.83 | -$2.18 | -19.1% | — | — | — |
Q3 FY2026
Aug 10, 2026
EPS Actual
—
EPS Est.
-$1.55
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$1.04
EPS Est.
-$1.51
EPS Surpr.
+31.1%
Revenue
—
Q1 FY2026
Mar 31, 2026Miss
EPS Actual
-$1.41
EPS Est.
-$1.17
EPS Surpr.
-20.5%
Revenue
—
Q4 FY2025
Nov 10, 2025Beat
EPS Actual
-$1.31
EPS Est.
-$1.55
EPS Surpr.
+15.5%
Revenue
—
Q3 FY2025
Aug 11, 2025Miss
EPS Actual
-$1.87
EPS Est.
-$1.60
EPS Surpr.
-16.9%
Revenue
—
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$2.09
EPS Est.
-$1.64
EPS Surpr.
-27.4%
Revenue
—
Q1 FY2025
Mar 13, 2025Miss
EPS Actual
-$2.74
EPS Est.
-$1.71
EPS Surpr.
-60.2%
Revenue
$0.00B
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$2.18
EPS Est.
-$1.83
EPS Surpr.
-19.1%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-1.35 | $-1.35 | $-1.35 | 1 |
| Q3 FY2026 | $-2.09 | $-1.34 | $-0.79 | 2 |
| Q2 FY2026 | $-1.95 | $-1.55 | $-1.33 | 2 |
| Q1 FY2026 | $-1.86 | $-1.51 | $-1.29 | 2 |
| Q4 FY2025 | $-1.20 | $-1.17 | $-1.12 | 1 |
| Q3 FY2025 | $-1.55 | $-1.55 | $-1.55 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +31.1% | $6.17 | $6.02 | -2.43% |
| ▼ Q1 FY2026 | Mar 31, 2026 | -20.5% | $4.25 | $5.12 | +20.47% |
| ▲ Q4 FY2025 | Nov 10, 2025 | +15.5% | $12.15 | $11.76 | -3.21% |
| ▼ Q3 FY2025 | Aug 11, 2025 | -16.9% | $11.15 | $10.94 | -1.88% |
| ▼ Q2 FY2025 | May 8, 2025 | -27.4% | $16.27 | $15.50 | -4.73% |
| ▼ Q1 FY2025 | Mar 13, 2025 | -60.2% | $17.67 | $17.45 | -1.25% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -19.1% | $15.91 | $16.29 | +2.39% |
| ▲ Q3 FY2024 | Aug 7, 2024 | +88.2% | $6.36 | $6.21 | -2.36% |
Q2 FY2026-2.43%
Report Date
May 7, 2026
EPS Beat/Miss
+31.1%
Price Before
$6.17
Price After
$6.02
Q1 FY2026+20.47%
Report Date
Mar 31, 2026
EPS Beat/Miss
-20.5%
Price Before
$4.25
Price After
$5.12
Q4 FY2025-3.21%
Report Date
Nov 10, 2025
EPS Beat/Miss
+15.5%
Price Before
$12.15
Price After
$11.76
Q3 FY2025-1.88%
Report Date
Aug 11, 2025
EPS Beat/Miss
-16.9%
Price Before
$11.15
Price After
$10.94
Q2 FY2025-4.73%
Report Date
May 8, 2025
EPS Beat/Miss
-27.4%
Price Before
$16.27
Price After
$15.50
Q1 FY2025-1.25%
Report Date
Mar 13, 2025
EPS Beat/Miss
-60.2%
Price Before
$17.67
Price After
$17.45
Q4 FY2024+2.39%
Report Date
Nov 7, 2024
EPS Beat/Miss
-19.1%
Price Before
$15.91
Price After
$16.29
Q3 FY2024-2.36%
Report Date
Aug 7, 2024
EPS Beat/Miss
+88.2%
Price Before
$6.36
Price After
$6.21
Avg Beat Reaction-2.67%
Avg Miss Reaction+3.00%
Beat Rate3 / 8 quarters
Largest Move+20.47% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CVKD ends December
Cadrenal Therapeutics, Inc. Common Stock (CVKD) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-1.04 — beating the analyst consensus of $-1.51 by +31.1%. The next CVKD earnings date is expected around September 1, 2026.
Each quarter, investors track CVKD earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CVKD revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CVKD's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CVKD earnings · 5 questionsCadrenal Therapeutics, Inc. Common Stock's next earnings report is expected around September 1, 2026. CVKD typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CVKD historically reports after market close (AMC).
CVKD earnings datewhen is CVKD earningsCVKD next earnings datewhen does CVKD report earningsCVKD earnings calendar
▸ Source: FMP · Cadrenal Therapeutics, Inc. Common Stock SEC filings · US GAAP · Cadrenal Therapeutics, Inc. Common Stock SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026